Reply

摘要

We thank Utman and Dhillon for their interest in our article.1 They expressed their concern that in some eyes in our cohort the intraocular pressure (IOP) increase, associated with intravitreal injection (0.05 mL) of bevacizumab, could have been of clinical significance in eyes with preexisting optic nerve head damage and provided results of a study to support their concern.2 However, that study was of a young (mean age, 28.9 years) myopic population and did not report a volume-dependent IOP increase. The average age of our cohort was 79.4 years. Therefore, it is absolutely inaccurate to extrapolate the results of triat study to our results. Moreover, Jonas et al,3 who studied a glaucoma-tous population, failed to find any morphologic optic disk changes after short-term increases in IOP.